The whole point - they don't want to pay for continuous treatment. The whole new idea is to treat with biologic until clinical remission, pull the treatment and add low dose DMARD to prevent flares. Saves money for some third party. Seriously, it's going to fail before it even starts. Can't force people to take medication, and there isn't any incentive if you're clear.
Clinical factors affecting quality of the response to Stelara for psoriasis
|
« Next Oldest | Next Newest »
|
Possibly Related Threads… | |||||
Thread | Author | Replies | Views | Last Post | |
Stelara vs Tremfya German study | Fred | 1 | 2,087 |
Thu-20-07-2023, 07:24 AM Last Post: Caroline |
|
Tremfya vs Stelara Italian study | Fred | 2 | 2,384 |
Fri-27-01-2023, 12:39 PM Last Post: Fred |
|
Otezla (apremilast) quality of life, efficacy, and safety study | Fred | 1 | 1,960 |
Tue-01-11-2022, 03:14 AM Last Post: mataribot |
|
Tremfya super response study | Fred | 4 | 3,398 |
Thu-04-08-2022, 19:34 PM Last Post: mataribot |
|
IMG-004 starts phase I clinical trial | Fred | 2 | 2,073 |
Tue-17-05-2022, 06:48 AM Last Post: Caroline |
Users browsing this thread: 2 Guest(s)